Theratechnologies Inc. Closes a US $46 Million Bought-Deal Public Offering

On January 19, 2021, Theratechnologies, a biopharmaceutical company focused on the development of innovative therapies which addresses unmet medical needs of HIV patients, closed a bought-deal public offering pursuant to which Theratechnologies issued 16,727,900 units at a price of US$2.75 per unit (equivalent to approximately C$3.51 per Unit) for aggregate gross proceeds of US$46,001,725 (equivalent to approximately C$58,714,929), including the full exercise of the over-allotment option to purchase an additional 2,181,900 Units at the offering price.

The Offering was led by Mackie Research Capital Corporation as the lead underwriter and sole bookrunner, on behalf of a syndicate of underwriters, including Canaccord Genuity Corp. and National Bank Financial Inc.